Astellas Pharma studied the potential of fezolinetant, a selective neurokinin-3 receptor (NK3R) antagonist, against hot flashes in a series of double-blinded and placebo-controlled trials.
With a $425 million upfront payment, Bayer bolstered the company’s women’s healthcare pipeline with the acquisition of U.K.-based KaNDy Therapeutics and an investigational treatment for menopause.
Novartis said Kisqali helped women with advanced breast cancer after menopause live longer, adding to data the Swiss company hopes will help convince doctors to choose the drug over Pfizer’s blockbuster Ibrance.
